In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Codexis (CDXS), with a price target of $22.50. The company’s shares opened today at $14.35, close to its 52-week low of $12.85.
According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.9% and a 28.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Gritstone Oncology Inc, and Trillium Therapeutics.
Codexis has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.05 and a one-year low of $12.85. Currently, Codexis has an average volume of 371.2K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, James Lalonde, the SVP, R&D of CDXS sold 19,999 shares for a total of $372,966.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics.
